Allogene Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $22 | $21 |
Gross Profit | -3,644 | -3,533 | -54,640 | |
EBITDA | -71,774 | -62,798 | -65,949 | -68,452 |
EBIT | -74,981 | -66,442 | -69,504 | -71,929 |
Net Income | -66,293 | -66,358 | -65,000 | -85,778 |
Net Change In Cash | 0 | 0 | 22 | 21 |
Free Cash Flow | -44,544 | -63,588 | -55,907 | -53,888 |
Cash | 51,239 | 170,667 | 51,039 | 83,155 |
Basic Shares | 209,188 | 190,026 | 169,128 | 168,335 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $95 | $243 | $38,489 | $38,345 |
Gross Profit | -242,819 | 243 | 38,489 | -11,541 |
EBITDA | -300,293 | -321,154 | -245,338 | -250,657 |
EBIT | -314,492 | -335,449 | -255,792 | -258,243 |
Net Income | -327,265 | -329,815 | -244,837 | -233,471 |
Net Change In Cash | 95 | 243 | 38,489 | 38,345 |
Cost of Revenue | -9,194 | 13,375 | ||
Free Cash Flow | -239,249 | -225,710 | -206,258 | -181,051 |
Cash | 83,155 | 576,471 | 809,481 | 1,032,118 |
Basic Shares | 156,931 | 143,147 | 135,820 | 120,370 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.32 |
2024-06-30 | -$0.35 |
2024-03-31 | -$0.38 |
2023-12-31 | -$0.43 |
